Proprietary AI analyst is now available

Genematrix Valuation Multiples

Discover Genematrix's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Genomtec, BCAL Diagnostics, Finemedix, Biosynex and more.

Genematrix Overview

About Genematrix

Genematrix Inc is a biotech company engaged in the development of the platform and molecular diagnostics products. Its products include NeoPlexTM STI-7 Detection kit, OmniPlex-HPV, PapilloTyper, HepB Typer-Adefovir, and HepB Typer-Precore among others.


Founded

2000

HQ

South Korea

Employees

N/A

Financials (FY)

Revenue: $7M
EBITDA: ($762K)

EV

$12M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Genematrix Financials

Genematrix reported last fiscal year revenue of $7M and negative EBITDA of ($762K).

In the same fiscal year, Genematrix generated $4M in gross profit, ($762K) in EBITDA losses, and had net loss of ($1M).


Genematrix P&L

In the most recent fiscal year, Genematrix reported revenue of $7M and EBITDA of ($762K).

Genematrix is unprofitable as of last fiscal year, with gross margin of 59%, EBITDA margin of (11%), and net margin of (17%).

See analyst estimates for Genematrix
Last FY202320242025202620272028
Revenue$7M$6M$7M$7M
Gross Profit$4M$3M$4M$4M
Gross Margin59%50%58%59%
EBITDA($762K)($112K)($2M)($762K)
EBITDA Margin(11%)(2%)(30%)(11%)
EBIT Margin(6%)(26%)(16%)(6%)
Net Profit($1M)($581K)($2M)($1M)
Net Margin(17%)(9%)(37%)(17%)
Net Debt$865K---

Financial data powered by Morningstar, Inc.

Genematrix Stock Performance

Genematrix has current market cap of $19M, and enterprise value of $12M.

Market Cap Evolution


Genematrix's stock price is $0.96.

Genematrix share price decreased by 23.7% in the last 30 days.

Genematrix has an EPS (earnings per share) of $-0.06.

See more trading valuation data for Genematrix
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$12M$19M-7.5%-23.7%--$-0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Genematrix Valuation Multiples

Genematrix trades at 1.7x EV/Revenue multiple, and (15.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Genematrix

Genematrix Financial Valuation Multiples

As of June 24, 2026, Genematrix has market cap of $19M and EV of $12M.

Genematrix has a P/E ratio of (16.0x).

Last FY202320242025202620272028
EV/Revenue1.7x1.8x1.8x1.7x
EV/EBITDA(15.1x)(103.1x)(5.9x)(15.1x)
EV/EBIT(26.1x)(7.0x)(10.8x)(26.1x)
EV/Gross Profit2.8x3.6x3.1x2.8x
P/E(16.0x)(32.8x)(7.8x)(16.0x)
EV/FCF14.5x(7.1x)(75.9x)14.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Genematrix Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Genematrix Margins & Growth Rates

In the most recent fiscal year, Genematrix reported gross margin of 59%, EBITDA margin of (11%), and net margin of (17%).

See estimated margins and future growth rates for Genematrix

Genematrix Margins

Last FY20242025202720282029
Gross Margin59%58%59%
EBITDA Margin(11%)(30%)(11%)
EBIT Margin(6%)(16%)(6%)
Net Margin(17%)(37%)(17%)
FCF Margin12%(2%)12%

Genematrix Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth2%6%
Gross Profit Growth19%9%
EBITDA Growth1639%(61%)
EBIT Growth(36%)(59%)
Net Profit Growth319%(51%)
FCF Growth(91%)(624%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Genematrix Operational KPIs

Access forward-looking KPIs for Genematrix
Last FY202320242025202620272028
S&M Expenses to Revenue6%8%8%6%
G&A Expenses to Revenue8%7%7%8%
R&D Expenses to Revenue26%35%33%26%
Opex to Revenue66%76%74%66%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Genematrix Competitors

Genematrix competitors include Genomtec, BCAL Diagnostics, Finemedix, Biosynex, Microba Life Sciences, Lifeward, Scandinavian Real Heart, Labo Euromedis, Iridex and Urteste.

Most Genematrix public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Genomtec70210.4x-(8.0x)-
BCAL Diagnostics10.2x10.2x(4.4x)-
Finemedix2.8x-(18.0x)-
Biosynex0.7x-58.1x-
Microba Life Sciences1.1x1.1x(1.7x)(1.5x)
Lifeward0.8x0.7x(1.0x)-
Scandinavian Real Heart--(5.3x)-
Labo Euromedis0.2x-9.6x-

This data is available for Pro users. Sign up to see all Genematrix competitors and their valuation data.

Start Free Trial

Investments by Genematrix

Genematrix has invested in 1 company to date.

Latest investment by Genematrix was on December 20th 2018. Genematrix invested in Barinthus Biotherapeutics in their $8M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Genematrix

Barinthus Biotherapeutics
Description
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
HQ CountryUnited Kingdom
HQ City
Oxford
Deal Date20 Dec 2018
RoundSeries A
Raised$8M
InvestorsKorea Investment Partners; Genematrix
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Genematrix investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Genematrix

When was Genematrix founded?Genematrix was founded in 2000.
Where is Genematrix headquartered?Genematrix is headquartered in South Korea.
Is Genematrix publicly listed?Yes, Genematrix is a public company listed on Korea Exchange.
What is the stock symbol of Genematrix?Genematrix trades under 109820 ticker.
When did Genematrix go public?Genematrix went public in 2009.
Who are competitors of Genematrix?Genematrix main competitors include Genomtec, BCAL Diagnostics, Finemedix, Biosynex, Microba Life Sciences, Lifeward, Scandinavian Real Heart, Labo Euromedis, Iridex, Urteste.
What is the current market cap of Genematrix?Genematrix's current market cap is $19M.
What is the current revenue of Genematrix?Genematrix's last fiscal year revenue is $7M.
What is the current EV/Revenue multiple of Genematrix?Current revenue multiple of Genematrix is 1.7x.
Is Genematrix profitable?No, Genematrix is not profitable.
How many companies Genematrix has acquired to date?Genematrix hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Genematrix has invested to date?As of June 2026, Genematrix has invested in 1 company.
What was the last Genematrix investment?On 20th December 2018 Genematrix invested in Barinthus Biotherapeutics, participating in a $8M Series A round, alongside Korea Investment Partners.
In what companies Genematrix invested in?Genematrix invested in Barinthus Biotherapeutics.

See public comps similar to Genematrix

Lists including Genematrix

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial